Study of three HIV drugs for adults with controlled HIV
Treatments studied
Part of Infections clinical trials.
This trial tests a new combination of three medications, lenacapavir, teropavimab, and zinlirvimab, for people with HIV who currently have undetectable virus levels on a stable oral treatment. The goal is to see if these drugs can keep the virus suppressed, possibly allowing a simpler treatment plan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been on a stable oral HIV medication for at least 6 months.
- Your viral load (amount of HIV in your blood) must be under 50 copies/mL at screening and for at least 6 months before.
- You cannot have had certain serious infections or conditions like tuberculosis or severe liver disease.
- You cannot have used specific long-acting or IV HIV treatments before, like lenacapavir or certain antibodies.
- You must have good kidney and liver function, and no active hepatitis B or C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving two experimental drugs together can help your immune system find and destroy hidden HIV cells. It aims to see if this approach can reduce the amount of virus in your body even while you're on your regular HIV medications.
This study tests whether combining two or more investigational drugs that can activate the hidden HIV reservoir in your body might help eliminate it. The goal is to see if this approach is safe and could help lead to a cure for HIV.
This study tests a new combination of two drugs to see if they can reduce the 'hidden' HIV that stays in your body even when you're on regular HIV treatment. The goal is to work toward a cure, not just control.
This study tests two drugs, baricitinib and sirolimus, alone or together, to see if they can help control HIV after you stop your usual HIV medications for a short time. The goal is to see if these drugs can keep the virus from rebounding.
This study tests a new long-acting HIV medication taken by mouth that may allow you to switch from your current daily pill. It is for people who have had an undetectable HIV viral load for at least 6 months and are currently on a stable HIV treatment.
This trial tests a long-acting injection called lenacapavir for children and teens with HIV who have tried other treatments and still have detectable virus. It may be an option if current medicines aren't working well enough.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.